Материалы 19-го Российского онкологического конгресса. Гематологическая секция «Лучевая терапия в онкогематологии» (ноябрь 2015 г., Москва)

СЪЕЗДЫ, КОНФЕРЕНЦИИ, СИМПОЗИУМЫ

ПРОШЛОЕ И НАСТОЯЩЕЕ ЛУЧЕВОЙ ТЕРАПИИ В ОНКОГЕМАТОЛОГИИ

С.И. Ткачев, д-р мед. наук

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России, Каширское ш., д. 24, Москва, Российская Федерация, 115478

Получено: 12 октября 2015 г.

Принято в печать: 23 декабря 2015 г.

Читать статью в PDFpdficon

ЛИТЕРАТУРА

  1. Kostakoglu L, Cheson BD. State-of-the-art research on “lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response”. Front Oncol. 2013;3:212. doi: 10.3389/fonc.2013.00212.
  2. Meignan M, Hutchings M, Schwartz L. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. The Oncologist. 2015;20:890–5. doi: 10.1634/theoncologist.2015-0036.
  3. Omur O, Baran Y, Oral A, et al. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Diagn Interv Radiol. 2014;10:185–92. doi: 10.5152/dir.2013.13174.
  4. Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol. 2014;164:315–28. doi: 10.1111/bjh.12601.
  5. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58. doi: 10.1200/jco.2013.53.5229.
  6. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32:3059–67. doi: 10.1200/jco.2013.54.8800.
  7. Cheng G, Alavi A. Value of 18F-FDG PET versus iliac biopsy in the initial evaluation of bone marrow infiltration in the case of Hodgkin’s disease: a meta-analysis. Nucl Med Commun. 2013;34(1):25–31. doi: 10.1097/mnm.0b013e32835afc19.
  8. Chen YK, Yeh CL, Tsui CC, et al. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: A meta-analysis. Clin Nucl Med. 2011;36:553–9. doi: 10.1097/rlu.0b013e318217aeff.
  9. Hutchings M. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Hematol Oncol Clin North Am. 2014;28(1):87–103. doi: 10.1016/j.hoc.2013.10.008.
  10. Gallamini A, Barringtom S, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematol. 2014;99(6):1107–13. doi: 10.3324/haematol.2013.103218.
  11. Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284–92. doi: 10.1016/s1470-2045(15)70013-6.
  12. Haznedar R, Aki SZ, Akdemir OU, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046–53. doi: 10.1007/s00259-011-1738-8.
  13. Zamagni E, Nanni C, Tacchetti P, et al. Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. Clin Lymph Myel Leuk. 2014;14(3):e101–4. doi: 10.1016/j.clml.2013.12.014.
  14. Lee E, Lee H, Lee SJ, et al. Baseline F-18 FDG PET uptake of bone marrow as a survival predictor in patients with multiple myeloma. Clin Lymph Myel Leuk. 2015;15(Suppl. 3):e114–5. doi: 10.1016/j.clml.2015.07.295.
  15. Meignan M. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis. Hematol Oncol. 2015;33:38–41. doi: 10.1002/hon.2214.